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Resistance to antimicrobials is a growing crisis
in clinical medicine, and it is generally recog-
nized that misuse and overuse in any sector
contributes to this burden. Antimicrobial use
in food animal production is an area of con-
cern because the on-farm selection of antimi-
crobial-resistant zoonotic pathogens can lead
to human exposure and infection via various
pathways, including meat and poultry prod-
ucts. Fluoroquinolone use in poultry produc-
tion selects for fluoroquinolone-resistant
Campylobacter populations and is associated
with an increase in ﬂuoroquinolone-resistant
Campylobacter infections in humans via poul-
try exposure (Gupta et al. 2004, 2005).
Campylobacter is an important foodborne
zoonotic pathogen causing enteritis and diar-
rhea (campylobacteriosis). Campylobacter infec-
tion is also associated with a number of rare
neuropathologic sequelae, including Guillain-
Barré syndrome (Hughes et al. 1999). In the
United States, Campylobacter is the most com-
mon cause of bacterial diarrhea, with over a
million people estimated to be affected annu-
ally [Centers for Disease Control and
Prevention (CDC) 2005]. Campylobacteriosis
is typically self-limiting, with symptoms rarely
lasting more than 10 days (Butzler 2004;
CDC 2005); however, it can be fatal in more
vulnerable populations (Djuretic et al. 1996;
Manfredi et al. 1999; Tee and Mijch 1998). 
Indeed, antimicrobial therapy is essential
for elderly, pregnant, and immunocompro-
mised patients for whom hydration and
electrolyte maintenance may be insufficient
(Allos 2001). Until recently, ﬂuoroquinolones
were regularly prescribed for those requiring
antimicrobial therapy. However, a sharp
increase in the prevalence of ﬂuoroquinolone-
resistant Campylobacter, shown to occur in par-
allel with the use of ﬂuoroquinolones in U.S.
poultry production, has limited fluro-
quinolones’ effectiveness in the clinical setting
(Allos 2001; Collignon 2005; Gupta et al.
2004). Immunocompromised patients with
Campylobacter bacteremia often require a pro-
longed course of multiantimicrobial therapy
(Tee and Mijch 1998); therefore, the loss of
ﬂuoroquinolones as an effective therapeutic has
become a threat to these patients. 
Based on a risk assessment of the contri-
bution of fluoroquinolone use in poultry
production to fluoroquinolone-resistant
Campylobacter infections in humans, the
Food and Drug Administration (FDA) sus-
pended all fluoroquinolone use in poultry
production as of 12 September 2005 (FDA
2000). The goal of this policy is to eliminate
on-farm selection of ﬂuoroquinolone-resistant
Campylobacter and thereby reduce human
exposure via food to these organisms.
However, this policy’s efﬁcacy may be limited
by stable reservoirs of fluoroquinolone-resis-
tant Campylobacter strains in and around
poultry production facilities. These reservoirs
can serve to sustain resistant Campylobacter in
poultry environments, even after the cessation
of on-farm fluoroquinolone use (Bull et al.
2006; Moore et al. 2006). Furthermore, some
studies indicate that ﬂuoroquinolone-resistant
Campylobacter isolates may actually be more
ﬁt than the wild-type with respect to poultry
colonization (Zhang et al. 2006). Therefore,
to better assess this policy’s efﬁcacy, it is essen-
tial to monitor the prevalence of resistant
strains in poultry ﬂocks, production facilities,
consumer poultry products, and human infec-
tions. If resistant strains continue to persist in
spite of the fluoroquinolone ban, it may be
necessary to implement other measures in
order to reduce fluoroquinolone-resistant
Campylobacter populations.
Previously, we reported that poultry
products from two conventional producers
were more likely to be contaminated with
ﬂuoroquinolone-resistant Campylobacter than
products from producers who claimed to use
no antibiotics (Price et al. 2005), even though
both conventional producers had announced
discontinuation of ﬂuoroquinolone use 1 year
before the study. Because of the relatively
short period of time between this announce-
ment and our analysis, we undertook the cur-
rent study of products for an additional
3 years (i.e., 4 years beyond the point at
which these two companies committed to
stop using ﬂuoroquinolones).
Methods
Poultry producers. We included products from
ﬁve different poultry producers in the present
study: A) Bell & Evans (Fredericksburg, PA);
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BACKGROUND: The use of antibiotics in food animal production has been associated with antibiotic-
resistant infections in humans. In 2005, the Food and Drug Administration (FDA) banned
fluoroquinolone use in U.S. poultry production in order to reduce the prevalence of fluoro-
quinolone-resistant Campylobacter. Little is known about the potential efﬁcacy of this policy.
OBJECTIVES: Our primary objective was to follow temporal changes in the prevalence of fluoro-
quinolone-resistant Campylobacter among poultry products from two conventional producers who
announced their cessation of ﬂuoroquinolone use in 2002 (3 years before the FDA’s ban). Our sec-
ondary objective was to compare, over time, the prevalence of fluoroquinolone-resistant
Campylobacter in conventional poultry products to those from producers who claim to use no
antibiotics.
METHODS: We collected poultry samples from two conventional producers and three antibiotic-
free producers over the course of 20 weeks in 2004 (n = 198) and 15 weeks in 2006 (n = 210). We
compared the rates of ﬂuoroquinolone resistance among Campylobacter isolates from the different
producers. 
RESULTS: We found no significant change in the proportion of fluoroquinolone-resistant
Campylobacter isolates from the two conventional producers over the study period. In addition,
Campylobacter strains from the two conventional producers were significantly more likely to be
ﬂuoroquinolone resistant than those from the antibiotic-free producers. 
CONCLUSIONS: The results from this study indicate that ﬂuoroquinolone-resistant Campylobacter
may be persistent contaminants of poultry products even after on-farm fluoroquinolone use has
ceased. The FDA’s ban on ﬂuoroquinolones in poultry production may be insufﬁcient to reduce
resistant Campylobacter in poultry products.
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(Stevens, PA); D) Perdue (Salisbury, MD); and
E) Tyson (Springdale, AR). Producers A–C
claim that their chickens are raised without any
antibiotics, including fluoroquinolones. We
refer to these producers and their products as
“antibiotic-free.” Producers D and E do not
claim general prohibitions on antibiotics; we
refer to these producers and their products as
“conventional.” A critical caveat to this desig-
nation is that each of the conventional produc-
ers announced separately in February 2002
that they had adopted company policies pro-
hibiting the use of fluoroquinolones. In the
same announcement, producer D claimed that
no ﬂuoroquinolones had been used in the year
before the announcement. Finally, all produc-
ers except producer C claimed to exclusively
slaughter their own ﬂocks in their processing
plants. Representatives from producer C
acknowledged that “custom ﬂocks,” including
those treated with antibiotics, were occasion-
ally processed in their facilities during the
study period.
Sampling and enrichment. We purchased
fresh chicken products from grocery stores in
the Baltimore, Maryland, area on a weekly
basis from 19 January 2004 to 7 June 2004
and from 20 February 2006 to 5 June 2006.
Two to three packages from each of the five
producers were purchased each time (except
when availability was limited). Thighs and
legs (bone-in and skin-on) were the default
cuts for the study. However, these cuts were
not consistently available for all producers; in
those cases, we tested alternative cuts, includ-
ing breasts, quarters, and whole chickens.
Packages were refrigerated at 4°C until they
were sampled (within 48 hr of purchase). A
single piece of chicken was sampled from each
package as follows. First, each package was
wiped with 70% ethanol and cut open with a
new disposable razor blade; the plastic cover
was then removed and photocopied for our
records. We used sterile forceps to transfer the
entire piece of chicken to a stomacher bag
containing 200 mL sterile Bolton broth
(Oxoid, Hampshire UK) supplemented with
laked horse blood (Quad Five, Ryegate, MT);
samples were shaken by hand for 2 min, the
chicken was removed using forceps, and the
bag was sealed 1–2 cm above the top of the
broth. Enrichments were incubated at 42°C
for 22–26 hr (Hunt 2000; Price et al. 2005). 
Isolation. Ten microliters of the enrichment
(~ 106 colony forming units) was streaked onto
CCDA (blood-free Campylobacter medium;
Oxoid) and incubated for 22–26 hr at 42°C. A
single typical Campylobacter colony was trans-
ferred to a fresh CCDA plate and streaked for
isolated colonies (this process was repeated
once to insure the isolation of a single strain).
A single puriﬁed colony was then streaked for
conﬂuent growth on CCDA and incubated for
22–26 hr. A 10-µL loop-full of cellular mater-
ial was transferred to Campylobacter freezing
medium (Hunt 2000), frozen on dry ice, and
stored at –80°C.
DNA isolation. DNA was isolated using a
rapid freeze–thaw method. Brieﬂy, one 10-µL
loop-full of cellular material was transferred
to 150 µL Tris-EDTA in a 200-µL capacity
polymerase chain reaction (PCR) tube or
96-well PCR plate. Cellular suspensions were
covered and placed in a chilled aluminum
block on dry ice for 2 min. Frozen cellular
suspensions were then heated in a 95°C alu-
minum block for 2 min. This process was
repeated three times, ending with a final
denaturing step of 95°C for 10 min. Cellular
debris was pelleted by centrifugation, and
100 µL supernatant was transferred to a fresh
PCR tube or 96-well PCR plate. 
Species conﬁrmation. Presumptive Campy-
lobacter isolates were confirmed and the
species identiﬁed using a PCR ampliﬁcation/
restriction digest described previously
(Engvall et al. 2002). Brieﬂy, THERM1 and
THERM4 PCR primers were used to amplify
a region of DNA specific to thermophilic
members of the genus Campylobacter. This
PCR product was then digested in two sepa-
rate reactions using the restriction endo-
nucleases, AluI and Tsp509I (New England
Biolabs, Ipswich, MA). The restriction pat-
terns produced from this digestion are distinc-
tive among the thermophilic Campylobacter
species (Engvall et al. 2002). 
Susceptibility. Susceptibility to fluoro-
quinolone was determined using standard
Clinical and Laboratory Standards Institute
methods and Campylobacter-speciﬁc methods
described previously by McDermott and
Walker (2003). Brieﬂy, Campylobacter isolates
were grown overnight on CCDA under micro-
aerophilic conditions. Colonies were sus-
pended to approximately 0.5 McFarland
standard in Mueller-Hinton broth and inocu-
lated onto Mueller-Hinton agar supplemented
with 5% sheep blood and ciprofloxacin
(USBiological, Swampscott, MA) at concentra-
tions of 0.12–32 µg/mL. Plates were grown
22–26 hr at 42°C under microaerophilic con-
ditions. The reference strain used was
Campylobacter jejuni (ATCC 33560; American
Type Culture Collection, Manassas, VA).
Strains were designated resistant if their mini-
mal inhibitory concentration was ≥ 4 µg/mL. 
Statistical analysis. We performed statisti-
cal analyses using Stata 8.0 (StataCorp,
College Station, TX). Chi-square analysis was
used to compare the proportions of samples
testing positive for Campylobacter and those
positive for Campylobacter resistant to ﬂuoro-
quinolones. Relative proportions with corre-
sponding 95% conﬁdence intervals (CIs) were
computed for all pair-wise comparisons of
producers. We detected no ﬂuoroquinolone-
resistant Campylobacter isolates from two pro-
ducers in 2006 (Table 1); zeros were replaced
with ones for relative proportion calculations
involving these producers. We used univariate
analysis to examine the association between
species and ﬂuoroquinolone resistance.
Results
Fluoroquinolone resistance. Overall, 13% of
Campylobacter isolates were resistant to ﬂuoro-
quinolones in 2004 and 21% in 2006 (a non-
signiﬁcant increase; p = 0.06) (Table 1). The
proportion of Campylobacter isolates resistant
to fluoroquinolones did not change signifi-
cantly between the two test periods for any
particular producer (Table 1). The proportion
of resistant isolates from the two conventional
producers was consistent with those collected
in 2003 (Price et al. 2005).
Pair-wise comparisons revealed signiﬁcant
differences in the proportion of fluoro-
quinolone-resistant Campylobacter among the
different producers. Without exception,
Campylobacter from conventional products
were more likely to be ﬂuoroquinolone resistant
than Campylobacter isolated from antibiotic-free
products (Table 2). Fluoroquinolone resis-
tance was signiﬁcantly more prevalent among
isolates from conventional products compared
with antibiotic-free products (Table 2). These
Price et al.
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Table 1. Prevalence of Campylobacter and ﬂuoroquinolone-resistant Campylobacter among producers in
2004 and 2006.
2004 2006
Percent (no.)  Percent (no.) 
No. of Percent (no.)  FQ-resistant  No. of Percent (no.)  FQ-resistant 
Producer samples Campylobactera Campylobacterb samples Campylobactera Campylobacterb
Antibiotic-free
A 40 67.5 (27) 3.7 (1) 45 66.7 (30) 0.0 (0)
B 38 63.2 (24) 4.2 (1) 33 90.9 (30)c 0.0 (0)
C 40 92.5 (37) 2.7 (1) 42 95.2 (40) 15.0 (6)
Conventional
D 40 62.5 (25) 24.0 (6) 45 77.8 (35) 37.1 (13)
E 40 97.5 (39) 28.2 (11) 45 93.3 (42) 42.9 (18)
Total 198 76.8 (152) 13.2 (20) 210 84.3 (177) 20.9 (37)
FQ, ﬂuoroquinolone.
aPercentage of samples contaminated with Campylobacter (susceptible or resistant). bPercentage of Campylobacter iso-
lates resistant to ﬂuoroquinolone. cSigniﬁcant increase over the 2004 proportion (p < 0.05).data were consistent with previous product
surveys (Cui et al. 2005; Price et al. 2005), as
well as with an on-farm study that showed
conventionally raised poultry are more likely
to be colonized with fluoroquinolone-resis-
tant Campylobacter compared with those
raised under the U.S. Department of
Agriculture (USDA) organic label guidelines
(Luangtongkum et al. 2006). 
Campylobacter contamination. Campylo-
bacter (undifferentiated by fluoroquinolone
resistance) was detected on 77% and 84% of
all the chicken products tested in 2004 and
2006, respectively (Table 1), again consistent
with previous studies (Cui et al. 2005; Price
et al. 2005). Among the ﬁve producers, only
producer B (antibiotic-free) was signiﬁcantly
more contaminated in 2006 than in 2004
(p = 0.006). The reason for this increase is not
known, but the increase may reflect changes
in production methods that are beyond the
scope of this article.
In our pair-wise analysis, significant dif-
ferences in the prevalence of Campylobacter
contamination were shown both among the
three antibiotic-free producers and between
the two conventional producers. We also
found signiﬁcant differences in the prevalence
of Campylobacter contamination between spe-
ciﬁc antibiotic-free and conventional produc-
ers, but there was no overall difference
between the two groups (conventional vs.
antibiotic-free) in either year (Table 3). 
Of the isolates, 92% were identified as
either Campylobacter coli (36%) or C. jejuni
(56%). One isolate was identified as being
Campylobacter lari, and the remaining isolates
were identified as Campylobacter spp., based
on standard phenotypic analysis. We found no
significant difference in the prevalence of
ﬂuoroquinolone resistance between the C. coli,
C. jejuni, or Campylobacter spp. collected in
this study (C. lari was too rare to contribute
signiﬁcantly to this assessment).
Discussion
This is the ﬁrst published study reporting the
temporal trends in fluoroquinolone-resistant
Campylobacter on poultry products from two
major U.S. broiler producers after they volun-
tarily ceased using ﬂuoroquinolones for broiler
production. The results of this study indicate
that ﬂuoroquinolone-resistant Campylobacter
may be persistent contaminants of poultry
products for years after on-farm fluoro-
quinolone use has ended.
Sustained resistance. Poor hygiene prac-
tices and insufﬁcient biosecurity measures may
play critical roles in sustaining fluoroquino-
lone-resistant Campylobacter populations
(Moore et al. 2006; Newell and Fearnley
2003). In the United States, protocols for
cleaning broiler chicken houses range from
removing the upper layer of litter between
every ﬂock to reusing litter for multiple ﬂocks
before removal (Morison C, personal commu-
nication). Complete Campylobacter decontami-
nation is probably rare under any standard
practice, and contaminated litter can be a sig-
niﬁcant source of Campylobacter carryover and
colonization in poultry houses (Petersen and
Wedderkopp 2001). Campylobacter in poultry
house water distribution systems is another
potential reservoir of resistant strains. Although
individual Campylobacter cells are sensitive to
many common disinfectants, they can form
disinfectant-resistant bioﬁlms in the water dis-
tribution systems of poultry houses (Trachoo
and Frank 2002; Trachoo et al. 2002).
Campylobacter can also reside in protozoa that
contaminate water distribution systems,
thereby increasing their resistance to chemical
disinfectants (Snelling et al. 2005).
Colonization with fluoroquinolone-
resistant Campylobacter is not limited to
Campylobacter sources within the broiler
facility; the immediate external environment
has also been shown to be an important
source of Campylobacter for colonization.
Once a ﬂock becomes colonized with ﬂuoro-
quinolone-resistant Campylobacter, these
resistant organisms can be pumped into the
environment via tunnel ventilation systems.
Campylobacter has been detected in the air up
to 30 m downwind of facilities housing colo-
nized flocks (Bull et al. 2006). In addition,
wild birds and surface waters can also become
colonized or contaminated with fluoro-
quinolone-resistant Campylobacter, thereby
becoming reservoirs for subsequent flocks
(Bull et al. 2006; Chuma et al. 2000;
Waldenstrom et al. 2005). Finally, recent
studies have demonstrated that houseﬂies can
carry Campylobacter and that these flies are
undeterred by conventional biosecurity meas-
ures, with as many as 30,000 entering a facil-
ity during a single ﬂock rotation (Hald et al.
2004). The combination of environmental,
animal, and insect reservoirs and potential car-
riers provide signiﬁcant challenges to poultry
producers who wish to eliminate the fluoro-
quinolone-resistant Campylobacter colonizing
their ﬂocks.
The continued presence of fluoro-
quinolone-resistant Campylobacter on poultry
products may be a result of more than conta-
mination in and around farms. Controlled
physiology experiments indicate that ﬂuoro-
quinolone-resistant strains may be more fit
than wild-type Campylobacter in their ability to
Fluoroquinolone-resistant Campylobacter persists on poultry products
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Table 2. Relative proportions of ﬂuoroquinolone-resistant Campylobacter among producers.
2004 2006
Reference  Comparison  Relative proportion  Relative proportion 
producer producer resistant (95% CI) p-Value resistant (95% CI) p-Value
Aa B 1.1 (0.1–17.0) 0.932 > 1.0 (0.1–15.3) 1.000
C 0.7 (0.0–11.2) 0.820 > 4.5 (0.6–35.4) 0.107
D 6.5 (0.8–50.1) 0.032 > 11.1 (1.5–80.3) 0.001
E 7.6 (1.0–55.6) 0.011 > 12.9 (1.8–91.1) 0.000
Ba C 0.6 (0.0–9.9) 0.754 > 4.5 (0.6–35.4) 0.107
D 5.8 (0.7–44.4) 0.047 > 11.1 (1.5–80.3) 0.001
E 6.8 (0.9–49.2) 0.018 > 12.9 (1.8–91.1) 0.000
C D 8.9 (1.1–69.3) 0.009 2.5 (1.1–5.8) 0.028
E 10.4 (1.4–76.9) 0.002 2.9 (1.3–6.5) 0.006
D E 1.2 (0.5–2.8) 0.710 1.2 (0.7–2.0) 0.611
Antibiotic-free Conventional 7.8 (2.4–25.5) 0.000 5.0 (2.5–10.3) 0.000
The relative proportion resistant is the proportion of ﬂuoroquinolone-resistant Campylobacter from the comparison pro-
ducer divided by the proportion of ﬂuoroquinolone-resistant Campylobacter from the reference producer. Each producer
was compared with every other producer in a pair-wise fashion.
aZero counts were replaced with 1 in order to estimate relative proportions; “>” indicates that the replacement of zero
values results in an underestimate of the actual relative proportions.
Table 3. Relative proportions of Campylobacter contamination (susceptible and resistant) among producers. 
2004 2006
Reference  Comparison  Relative proportion  Relative proportion 
producer producer contaminated (95% CI) p-Value contaminated (95% CI) p-Value
A B 0.9 (0.7–1.3) 0.687 1.4 (1.1–1.7) 0.012
C 1.4 (1.1–1.7) 0.005 1.4 (1.1–1.8) 0.001
D 0.9 (0.7–1.3) 0.639 1.2 (0.9–1.5) 0.239
E 1.4 (1.2–1.8) 0.000 1.4 (1.1–1.7) 0.002
B C 1.5 (1.1–1.9) 0.002 1.0 (0.9–1.2) 0.456
D 1.0 (0.7–1.4) 0.952 0.9 (0.7–1.0) 0.124
E 1.5 (0.2–0.5) 0.000 1.0 (0.9–1.2) 0.691
C D 0.7 (0.5–0.9) 0.001 0.8 (0.7–1.0) 0.018
E 1.1 (1.0–1.2) 0.305 1.0 (0.9–1.1) 0.703
D E 1.6 (1.2–2.0) 0.000 1.2 (1.0–1.4) 0.036
Antibiotic-free Conventional 1.1 (0.9–1.2) 0.375 1.0 (0.9–1.2) 0.662
The relative proportion contaminated is the proportion of products contaminated with Campylobacter from the compari-
son producer divided by the proportion of products contaminated with Campylobacter from the reference producer. Each
producer was compared with every other producer in a pair-wise fashion.Price et al.
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both colonize and persist in the gut of chickens
(Zhang et al. 2006). If these ﬁndings hold true
in the setting of real-world poultry facilities,
merely removing the fluoroquinolones from
production may be insufﬁcient to reduce the
prevalence of resistant strains. 
Although the present study does not
include samples from before the voluntary
cessation of ﬂuoroquinolone use by two con-
ventional producers, it clearly shows that the
prevalence of fluoroquinolone-resistant
Campylobacter is not decreasing on their
products in the years following cessation and
has not decreased to the level found on the
products of antibiotic-free producers who
claim no history of ﬂuoroquinolone use. On
the other hand, this study also shows that the
resistance is not increasing significantly. In
Spain, where fluoroquinolones were used
heavily in poultry production, approximately
99% of poultry-associated Campylobacter iso-
lates were ﬂuoroquinolone resistant in the late
1990s (Garau et al. 1999; Saenz et al. 2000).
Compared with this, holding the proportion
of Campylobacter resistant to ﬂuoroquinolones
< 50% may be considered, by some, to be a
victory.
Antibiotic-free versus conventional prod-
ucts. Consistent with our previous study (Price
et al. 2005), Campylobacter isolates from anti-
biotic-free products were signiﬁcantly less likely
to be ﬂuoroquinolone resistant than those from
conventional producers. The substantial,
although not statistically signiﬁcant, increase
from 2004 to 2006 in ﬂuoroquinolone-resistant
strains among Campylobacter isolated from the
antibiotic-free producer C may be due to cross-
contamination from processing equipment
previously used to slaughter conventional
ﬂocks. Producer C was the only antibiotic-free
producer that processed both antibiotic-free
and conventional flocks in their processing
facilities during the time of the study. 
Such cross-contamination may take place
in conventional processing facilities as well.
For example, it is feasible that some growers
who raise chickens under contract with con-
ventional producers have no history of on-
farm ﬂuoroquinolone use. These growers may
raise flocks that become cross-contaminated
by slaughter equipment in conventional
slaughter facilities. Previous studies have
shown that cross-contamination is a regular
occurrence in processing plants (Newell et al.
2001). However, it should be emphasized
that antibiotic use on the farm is generally
dictated by the producers who control the
processing plants and with whom growers
contract.
Campylobacter contamination. The preva-
lence of Campylobacter (susceptible and resis-
tant) in poultry products varied significantly
among producers; however, there was no con-
sistent pattern with regard to antibiotic-use
group. These findings are consistent with
those from Denmark, where Campylobacter
contamination on poultry products did not
change signiﬁcantly after antimicrobials were
removed as feed additives (Evans and Wegener
2003). On-farm and processing plant prac-
tices, such as between-flock cleaning and
decontamination of slaughter equipment,
likely outweigh any impact from antimicrobial
use on general Campylobacter contamination.
Limitations of the study. The present
study had four primary limitations. First, the
study was limited in geographic region; how-
ever, despite this limitation, the results are
probably generalizable because integrator-
defined production methods vary little from
region to region. Moreover, broiler production
has become regionally concentrated in the
southeastern United States, and products from
this region are distributed widely throughout
the United States. Second, the study was lim-
ited in the number of producers included in
the study. We focused on conventional pro-
ducers D and E because they announced that
they had ceased using fluoroquinolones in
2002. The three antibiotic-free producers were
the only three with branded products consis-
tently available in the Baltimore area. Third,
we could not test the same cut each time from
each producer. Thighs and legs (bone-in, skin-
on) were the default cuts for the study; how-
ever, because these cuts were not consistently
available for some producers, alternative cuts
were tested occasionally. However, because
products were tested for the presence or
absence of Campylobacter rather than by
quantifying colony forming units, the choice
of cut probably had little, if any, impact on
the outcome of the study. Finally, actual use
of fluoroquinolones during the test period
could not be determined because information
on drug use in food animals is considered
proprietary and not subject to mandatory dis-
closure to regulatory bodies (National
Research Council 1999).
Public health implications. Fluoro-
quinolone-resistant Campylobacter strains
pose a significant public health threat in the
United States. In response to growing con-
cerns over the contribution of agricultural
antimicrobial use to resistant human infec-
tions, the FDA banned the use of fluoro-
quinolones in U.S. poultry production (FDA
2000). The results from the present study
indicate that fluoroquinolone-resistant
Campylobacter may be persistent contaminants
of poultry products even after on-farm ﬂuoro-
quinolone use has ceased. Thus, the FDA’s
policy alone may be insufﬁcient to reduce con-
sumer exposures to ﬂuoroquinolone-resistant
Campylobacter. Without additional interven-
tions, ﬂuoroquinolone-resistant Campylobacter
may continue to be a public health burden for
years after the FDA’s ban. 
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